培美曲塞联合铂类一线治疗晚期非鳞非小细胞肺癌的临床观察

doi:10.3969/j.issn.1007-3969.2014.08.009

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (8): 610-614.doi: 10.3969/j.issn.1007-3969.2014.08.009

培美曲塞联合铂类一线治疗晚期非鳞非小细胞肺癌的临床观察

陈文怡,王韡旻,姜丽岩,施春雷,熊丽纹,储天晴,裴俊,顾爱琴

上海交通大学附属胸科医院呼吸内科，上海 200030

出版日期:2014-08-30 发布日期:2014-11-07
通信作者: 顾爱琴　E-mail:guaiqin11@126.com

Clinical observation of efficacy and safety of pemetrexed plus platinum as the first–line chemotherapy with advanced non-squamous non-small cell lung cancer

CHEN Wen-yi, WANG Wei-min, JIANG Li-yan, SHI Chun-lei, XIONG Li-wen, CHU Tian-qing, PEI Jun, GU Ai-qin

Department of Respiratory Medicine, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200030, China

Published:2014-08-30 Online:2014-11-07
Contact: GU Ai-qin E-mail: guaiqin11@126.com

摘要/Abstract

摘要：

背景与目的：晚期肺癌一线化疗有效率仅30%～40%，本研究旨在探讨培美曲塞联合铂类药物(卡铂或顺铂)治疗晚期非鳞非小细胞肺癌(non-small cell lung cancer，NSCLC)的疗效及不良反应。方法：121例非鳞NSCLC患者，给予培美曲塞联合铂类化疗：培美曲塞500 mg/m2第1天，静脉滴注，卡铂300 mg/m2，第1天，静脉滴注，每3周重复；或培美曲塞500 mg/m2，第1天，静脉滴注，顺铂70 mg/m2，第1天，静脉滴注，每3周重复。上述方案连用2~6个周期，至少2个周期评价疗效。主要观察终点是疾病控制率(diseasecontrol rate，DCR)，其次是中位无进展生存时间(progression-free survival，PFS)、1年生存率和安全性。结果：全组可评价疗效121例，完全缓解(complete response，CR)1例，部分缓解(partial response，PR)44例，病情稳定(stable disease，SD)50例，疾病进展(progressive disease，PD)26例，客观有效率(objective response rate，ORR)为37.2%(45/121)，DCR为78.5%(95/121)，PFS为5.2个月(95%CI：4.4~6.0个月)，1年生存率为59.0%。其中培美曲塞联合卡铂组ORR为38.3%(23/60)，DCR为78.3%(47/60)，PFS为5.1个月(95%CI：3.8~6.4个月)，1年生存率55.2%；培美曲塞联合顺铂组ORR为36.1%(22/61)，DCR为78.7%(48/61)，PFS为6.2个月(95%CI：4.3~8.1个月)，1年生存率为62.5%。两组之间的ORR、DCR、PFS和1年生存率差异无统计学意义(P＞0.05)。主要不良反应为中性粒细胞和白细胞下降、乏力及胃肠道反应。结论：培美曲塞联合铂类药物一线治疗晚期非鳞NSCLC疗效确切，不良反应发生率低，耐受性较好。

关键词: 培美曲塞, 卡铂, 顺铂, 一线治疗, 晚期非小细胞肺癌

Abstract:

Background and purpose: The effective rate of first-line chemotherapy for advanced lung cancer is 30%-40%. The purpose of this study was to evaluate the efficacy and adverse effects of pemetrexed combined with carboplatin or cisplatin in the treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC). Methods: One hundrend and twenty-one patients with advanced non-squamous NSCLC were enrolled in this study and all of these patients had been confirmed with pathology or cytology. Among the 121 cases, 60 cases were male and 61 were female, the median age was 59 years, adnenocarcinoma in 113 patients and large cell carcinoma in 8 patients. Combination regimen: patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 or cisplatin 70 mg/m2 on day 1 by intravenous infusion, administrated every 3 weeks for 2 to 6 cycles. All patients who received 2 or more cycles could be evaluated. Disease control rate (DCR) was the primary end point; secondary end points included progression-free survival (PFS), 1-year survival rate and safety. Results: There was 1 case with complete response (CR), 44 cases achieved partial response (PR), 50 had stable disease (SD) and 26 cases had progressive disease (PD) in the overall cases. ORR and DCR were 37.2% (45/121) and 78.5% (95/121), respectively. The median PFS time was 5.2 months and 1-year survival rate was 59.0%. In pemetrexed combined with carboplatin group, the ORR and DCR were 38.3% (23/60) and 78.3% (47/60), respectively; The median PFS was 5.1 months (95%CI: 3.8-6.4 month) and 1-year survival rate was 55.2%. The patients treated with pemetrexed plus cisplatin, the ORR and DCR were 36.1% (22/61) and 78.7% (48/61), respectively. Median PFS was 6.2 months (95%CI: 4.3-8.1 month) and 1-year survival rate was 62.5%. There were no statistical differences between carboplatin/pemetrexed and cisplatin/pemetrexed for both ORR, DCR, PFS and 1-year survival rate (P>0.05). The major adverse effects were leukopenia, neutropenia, fatigue and gastrointestinal reaction. Conclusion: Pemetrexed plus platinum chemotherapy could be considered as the firstline treatment option for advanced non-squamous NSCLC patients. Pemetrexed combined with carboplatin/ cisplatin regimen has efficacy with mild toxicity and better tolerability.

Key words: Pemetrexed, Carboplatin, Cisplatin, First-line chemothrepay, Advanced non-small cell lung cancer

陈文怡,王韡旻,姜丽岩,施春雷,熊丽纹,储天晴,裴俊,顾爱琴. 培美曲塞联合铂类一线治疗晚期非鳞非小细胞肺癌的临床观察[J]. 中国癌症杂志, 2014, 24(8): 610-614.

CHEN Wen-yi, WANG Wei-min, JIANG Li-yan, SHI Chun-lei, XIONG Li-wen, CHU Tian-qing, PEI Jun, GU Ai-qin. Clinical observation of efficacy and safety of pemetrexed plus platinum as the first–line chemotherapy with advanced non-squamous non-small cell lung cancer[J]. China Oncology, 2014, 24(8): 610-614.

[1]	李瑞晓, 唐启胜, 马善金, 张　波, 李雪莲, 张志明 . NDRG2通过抑制Bcl-2表达增加膀胱癌细胞对顺铂的敏感性[J]. 中国癌症杂志, 2021, 31(4): 263-267.
[2]	施茂林, 柏玉娣, 王超, 李思琪, 周代君, 彭晶晶, 孙非凡, 李东, 张涛 . PD-L1表达对晚期肺腺癌患者培美曲塞化疗效果的影响及其机制[J]. 中国癌症杂志, 2021, 31(4): 308-316.
[3]	刘懿萱 , 文泽轩 , 郭　林 , 卢仁泉 . TTK1在卵巢癌铂类耐药中的生物学功能分析[J]. 中国癌症杂志, 2021, 31(3): 182-191.
[4]	马　倩, 刘懿萱, 开今言, 郭　林, 卢仁泉 . Ku86通过调控TOP1和COPS5影响上皮性卵巢癌细胞对于顺铂的化疗敏感性[J]. 中国癌症杂志, 2021, 31(2): 100-107.
[5]	俞　弋, 丛　青, 徐丛剑, 姜　伟. PAFR对卵巢癌细胞顺铂敏感性的影响及机制研究[J]. 中国癌症杂志, 2021, 31(11): 1063-1071.
[6]	祝开忠, 王挺锐, 陈焕雄, 陈　涛, 钟贞浩. 骨肉瘤中O-GlcNAc糖基转移酶的表达及其对增殖和顺铂敏感性的影响[J]. 中国癌症杂志, 2020, 30(9): 682-688.
[7]	李文成，王孝深. 铂类药物在头颈部鳞癌治疗中的选择与应用[J]. 中国癌症杂志, 2019, 29(4): 300-306.
[8]	王春晓, 邱成志, 洪钟时. 沉默GOLPH3基因表达逆转人结肠癌细胞顺铂耐药的研究[J]. 中国癌症杂志, 2019, 29(11): 862-868.
[9]	杨　颖，杨志芳，才　层，张瑞丽，路鹏霏，贾春丽，李志鹏，毛　睿，张　华，包永星. miR-27a-3p对肝癌细胞化疗敏感性的影响及机制探讨[J]. 中国癌症杂志, 2019, 29(10): 788-794.
[10]	李浩然,李梦娇,刘　霏,等. 糖代谢中关键酶果糖双磷酸酶-1与卵巢癌化疗敏感性关系的研究[J]. 中国癌症杂志, 2017, 27(5): 340-344.
[11]	陈　昊,周　鹏,徐晶晶,等. miR-17-92基因簇增强前列腺癌DU145细胞的迁移、侵袭能力及对顺铂的耐药性[J]. 中国癌症杂志, 2017, 27(2): 95-101.
[12]	刘红柳,杨家梅. 培美曲塞单药或联合吉非替尼治疗EGFR-TKI耐药后晚期非小细胞肺癌临床观察[J]. 中国癌症杂志, 2017, 27(2): 135-139.
[13]	胡章国,周　严,刘显勋,等. Ipilimumab联合化疗治疗晚期肺鳞癌的单中心安全性观察[J]. 中国癌症杂志, 2017, 27(1): 31-35.
[14]	冯　忻,王彩霞,欧志英. 重组人TRAIL蛋白联合顺铂对人卵巢癌细胞生长及凋亡的影响[J]. 中国癌症杂志, 2016, 26(8): 648-654.
[15]	张彭南,孙　红,蒋红元. miR-483-5p在上皮性卵巢癌中的表达及其对顺铂敏感性的影响[J]. 中国癌症杂志, 2016, 26(5): 394-398.

培美曲塞联合铂类一线治疗晚期非鳞非小细胞肺癌的临床观察

Clinical observation of efficacy and safety of pemetrexed plus platinum as the first–line chemotherapy with advanced non-squamous non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价